# Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

> **NCT03950141** · PHASE2 · UNKNOWN · sponsor: **Beijing Hospital** · enrollment: 30 (estimated)

## Conditions studied

- HER-2 Negatived Gastric Cancer

## Interventions

- **DRUG:** Apatinib and S-1

## Key facts

- **NCT ID:** NCT03950141
- **Lead sponsor:** Beijing Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2019-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950141, "Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03950141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*